CN116617356B - Alopecia preventing composition, and preparation method and application thereof - Google Patents
Alopecia preventing composition, and preparation method and application thereof Download PDFInfo
- Publication number
- CN116617356B CN116617356B CN202310886126.2A CN202310886126A CN116617356B CN 116617356 B CN116617356 B CN 116617356B CN 202310886126 A CN202310886126 A CN 202310886126A CN 116617356 B CN116617356 B CN 116617356B
- Authority
- CN
- China
- Prior art keywords
- parts
- solution
- hair
- composition
- matrine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 66
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 43
- 231100000360 alopecia Toxicity 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 80
- 230000003656 anti-hair-loss Effects 0.000 claims abstract description 53
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims abstract description 48
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 claims abstract description 41
- 229930014456 matrine Natural products 0.000 claims abstract description 41
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 claims abstract description 40
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 40
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 40
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims abstract description 38
- RZALONVQKUWRRY-FYZOBXCZSA-N 2,3-dihydroxybutanedioic acid;(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound OC(=O)C(O)C(O)C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O RZALONVQKUWRRY-FYZOBXCZSA-N 0.000 claims abstract description 26
- 229960003237 betaine Drugs 0.000 claims abstract description 26
- 229940035437 1,3-propanediol Drugs 0.000 claims abstract description 14
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims abstract description 14
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims abstract description 13
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims abstract 4
- 238000003756 stirring Methods 0.000 claims description 42
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 33
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 claims description 18
- RRJOMESUBQAYOA-BZSNNMDCSA-N (2S)-2-[[(2S)-2-[[2-[[(2S)-2-acetamido-6-aminohexanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-6-aminohexanamide Chemical compound NCCCC[C@H](NC(=O)C)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(N)=O)CC1=CN=CN1 RRJOMESUBQAYOA-BZSNNMDCSA-N 0.000 claims description 16
- 229960002685 biotin Drugs 0.000 claims description 16
- 235000020958 biotin Nutrition 0.000 claims description 16
- 239000011616 biotin Substances 0.000 claims description 16
- XLELDISCQSKJES-IPPMYLEBSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(tetradecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical compound CCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O XLELDISCQSKJES-IPPMYLEBSA-N 0.000 claims description 14
- 229940078015 myristoyl pentapeptide-4 Drugs 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000008367 deionised water Substances 0.000 claims description 11
- 229910021641 deionized water Inorganic materials 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 8
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 51
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 46
- 229920001184 polypeptide Polymers 0.000 abstract description 39
- 230000001737 promoting effect Effects 0.000 abstract description 36
- 230000000694 effects Effects 0.000 abstract description 30
- 210000004761 scalp Anatomy 0.000 abstract description 27
- 210000003780 hair follicle Anatomy 0.000 abstract description 26
- 210000004209 hair Anatomy 0.000 abstract description 21
- 108010076876 Keratins Proteins 0.000 abstract description 19
- 102000011782 Keratins Human genes 0.000 abstract description 18
- 230000037319 collagen production Effects 0.000 abstract description 13
- 230000003779 hair growth Effects 0.000 abstract description 13
- 238000004519 manufacturing process Methods 0.000 abstract description 13
- -1 glucosyl glycoside Chemical class 0.000 abstract description 11
- 230000003020 moisturizing effect Effects 0.000 abstract description 10
- 102000008186 Collagen Human genes 0.000 abstract description 9
- 108010035532 Collagen Proteins 0.000 abstract description 9
- 229920001436 collagen Polymers 0.000 abstract description 9
- 206010061218 Inflammation Diseases 0.000 abstract description 8
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 abstract description 8
- 230000004054 inflammatory process Effects 0.000 abstract description 8
- 241000894006 Bacteria Species 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 229930182470 glycoside Natural products 0.000 abstract description 6
- 230000003467 diminishing effect Effects 0.000 abstract description 4
- 210000000442 hair follicle cell Anatomy 0.000 abstract description 4
- 230000008439 repair process Effects 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 44
- 239000000243 solution Substances 0.000 description 42
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 239000013642 negative control Substances 0.000 description 14
- 239000013641 positive control Substances 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 11
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 9
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 9
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000003676 hair loss Effects 0.000 description 8
- 210000002510 keratinocyte Anatomy 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 208000024963 hair loss Diseases 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 239000003961 penetration enhancing agent Substances 0.000 description 6
- 102000004363 Aquaporin 3 Human genes 0.000 description 5
- 108090000991 Aquaporin 3 Proteins 0.000 description 5
- 102000004125 Interleukin-1alpha Human genes 0.000 description 5
- 108010082786 Interleukin-1alpha Proteins 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000002453 shampoo Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 241000555676 Malassezia Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000004519 grease Substances 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 3
- 108060000903 Beta-catenin Proteins 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229930182478 glucoside Natural products 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000002374 sebum Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- 102000015735 Beta-catenin Human genes 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000013814 Wnt Human genes 0.000 description 2
- 108050003627 Wnt Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 210000000887 face Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- VFKZECOCJCGZQK-UHFFFAOYSA-M 3-hydroxypropyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CCCO VFKZECOCJCGZQK-UHFFFAOYSA-M 0.000 description 1
- 102000010637 Aquaporins Human genes 0.000 description 1
- 108010063290 Aquaporins Proteins 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 102000004958 Caspase-14 Human genes 0.000 description 1
- 108090001132 Caspase-14 Proteins 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 244000007835 Cyamopsis tetragonoloba Species 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 229910002601 GaN Inorganic materials 0.000 description 1
- JMASRVWKEDWRBT-UHFFFAOYSA-N Gallium nitride Chemical compound [Ga]#N JMASRVWKEDWRBT-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 241000555688 Malassezia furfur Species 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010044625 Trichorrhexis Diseases 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000005183 environmental health Effects 0.000 description 1
- 229940023064 escherichia coli Drugs 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000004383 glucosinolate group Chemical group 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004565 granule cell Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003660 hair regeneration Effects 0.000 description 1
- 230000003659 hair regrowth Effects 0.000 description 1
- 210000004919 hair shaft Anatomy 0.000 description 1
- 230000003752 improving hair Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 108010028309 kalinin Proteins 0.000 description 1
- 229960001518 levocarnitine Drugs 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000006864 oxidative decomposition reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003658 preventing hair loss Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 238000002723 toxicity assay Methods 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/416—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to the field of anti-hair loss products, in particular to an anti-hair loss composition, a preparation method and application thereof. The composition comprises: matrine salicylic acid, L-carnitine tartaric acid, collagen production promoting polypeptide, keratin production promoting polypeptide, glyceroglycoside, and betaine 1, 3-propylene glycol. The composition aims at preventing alopecia from multiple dimensions, achieves effects of controlling oil, inhibiting bacteria and diminishing inflammation by using matrine salicylic acid, balances scalp environment, combines the moisturizing effect of glucosyl glycoside, and synergistically improves water-oil balance of scalp; the sub-health state of scalp of the alopecia crowd is corrected by utilizing the restoration capability of the glucosyl glyceroglycosides; the polypeptide which promotes collagen generation by utilizing the combination of the L-carnitine tartaric acid improves the activity of hair follicle cells, repairs the hair follicle structure and strengthens the hair root; promoting hair growth using a keratin-producing promoting polypeptide; betaine 1, 3-propanediol can deliver the composition and also act synergistically on the active.
Description
Technical Field
The invention relates to the field of anti-hair loss products, in particular to an anti-hair loss composition, and a preparation method and application thereof.
Background
Hair consists of two parts, the hair shaft and the hair root, which are essentially cellular proteins that are keratinized, and do not contain nerves and blood vessels. Hair follicles are tissues surrounding the root hair, normal viable hair follicles are connected to capillaries in the dermis through papilla at the bottom of the hair follicle, and nutrients are delivered to the hair through blood circulation. Collagen is an important nutrient for hair growth, and if the collagen at the root of the hair is sufficient, the collagen not only can promote the hair growth, but also can make the hair firm, tough and elastic.
Hair follicles on the scalp need to remain healthy for continued hair growth without loss of hair. When the scalp and hair follicles are affected by environmental factors, aging, etc., an imbalance in the level of free radicals is caused, the most direct manifestation of this imbalance is the change in scalp grease. The grease secreted by the scalp is idle, but under the action of bacteria and ultraviolet rays, decomposition and oxidation can generate harmful substances, and the harmful substances can damage the functions of mitochondria of cells in hair follicles, so that the cells are aged and dead, the hair follicles are damaged, and alopecia occurs.
Alopecia has physiological alopecia and pathological alopecia, and brings trouble to the psychology of people. However, the root causes are unhealthy scalp, blocked hair follicles, atrophy and degeneration, the atrophic degenerated hair follicles do not participate in the body circulation, so that the hair can not absorb nutrients, the hair can not grow naturally, and finally, phenomena such as alopecia, hair breakage and the like occur.
In the face of the problem of hair loss, copper peptides were found to stimulate the root follicles to produce hair. With the continued development of technology, more and more active peptides are used to address hair loss and promote hair regrowth. Products for preventing hair loss and growing hair by utilizing the polypeptide are more in the market, however, the effect is not ideal. This problem arises mainly for two reasons: on the one hand, most of the products only contain one polypeptide or contain a plurality of polypeptides, only pay attention to promoting hair growth, not pay attention to scalp environment and hair firmness, and have a single action mechanism; on the other hand, due to the existence of the skin barrier, the polypeptide in the product cannot be well absorbed through the skin barrier, and the efficacy of the composition is difficult to be exerted. In order to increase transdermal absorption, either the amount of the material to be administered is increased or a permeation enhancer such as ethanol is used in a large amount, which causes an increase in cost and a burden on the scalp.
Therefore, developing a composite raw material which can maintain scalp environment, promote hair growth, strengthen hair roots to prevent falling off, and be easy for skin absorption to achieve multi-dimensional falling-off prevention is important.
Disclosure of Invention
In view of the shortcomings of the prior art, the invention aims to provide an anti-hair loss composition, a preparation method and application thereof, wherein the anti-hair loss composition can act on a plurality of ways to achieve multi-dimensional anti-hair loss, and aims to solve the problems of single action mechanism and unsatisfactory effect of the existing anti-hair loss treatment products.
The technical scheme of the invention is as follows:
in a first aspect, the present invention provides an anti-hair loss composition comprising the following components: matrine salicylic acid, L-carnitine tartaric acid, collagen production promoting polypeptide, keratin production promoting polypeptide, glycerol Glucoside (GG), and betaine 1, 3-propylene glycol.
Optionally, the anti-hair loss composition comprises the following components in parts by weight: 1-10 parts of matrine salicylic acid, 0.5-20 parts of L-carnitine tartaric acid, 0.02-4 parts of polypeptide for promoting collagen production, 0.01-2 parts of polypeptide for promoting keratin production, 5-50 parts of GG (gallium nitride) -1, 3-propanediol and 5-50 parts of betaine.
Optionally, the polypeptide for promoting collagen production comprises the following components in parts by weight: 0.01-2 parts of biotin tripeptide-1 and 0.01-2 parts of acetyl tetrapeptide-3.
Alternatively, the polypeptide that promotes keratin production is myristoyl pentapeptide-4.
Optionally, the supramolecular penetration enhancer is betaine 1, 3-propanediol.
Optionally, the anti-hair loss composition comprises the following components in parts by weight: 1-10 parts of matrine salicylic acid, 0.5-20 parts of L-carnitine tartaric acid, 0.01-2 parts of biotin tripeptide-1, 0.01-2 parts of acetyl tetrapeptide-3, 0.01-2 parts of myristoyl pentapeptide-4, 5-50 parts of glyceroglycosides and 5-50 parts of betaine 1, 3-propylene glycol.
Optionally, the anti-hair loss composition comprises the following components in parts by weight: 3 parts of matrine salicylic acid, 0.5 part of L-carnitine tartaric acid, 0.2 part of biotin tripeptide-1, 0.2 part of acetyl tetrapeptide-3, 0.2 part of myristoyl pentapeptide-4, 20 parts of glyceroglycosides and 15 parts of betaine 1, 3-propanediol.
Optionally, the anti-hair loss composition further comprises a polyol preservative, preferably 1, 2-pentanediol.
In a second aspect, the present invention provides a method for preparing the anti-hair loss composition according to the present invention, comprising the steps of: matrine salicylic acid, L-carnitine tartaric acid, collagen production promoting polypeptide, keratin production promoting polypeptide, glyceroglycoside (GG) and betaine 1, 3-propylene glycol are mixed, and stirred to obtain the alopecia preventing composition.
Optionally, the method specifically comprises the following steps in parts by weight: 1-10 parts of matrine salicylic acid, 0.5-20 parts of L-carnitine tartaric acid, 0.02-4 parts of polypeptide for promoting collagen production, 0.01-2 parts of polypeptide for promoting keratin production, 5-50 parts of glyceroglycosides and 5-50 parts of betaine 1, 3-propanediol are mixed and stirred to obtain the alopecia preventing composition.
Optionally, the method specifically comprises the steps of:
mixing 3 parts of matrine salicylic acid with deionized water, and uniformly stirring to obtain a solution 1;
adding 0.5 part of L-carnitine tartaric acid into the solution 1, and uniformly stirring to obtain a solution 2;
adding 0.2 part of biotin tripeptide-1 into the solution 2, and uniformly stirring to obtain a solution 3;
adding 0.2 part of myristoyl pentapeptide-4 into the solution 3, and uniformly stirring to obtain a solution 4;
adding 0.2 part of acetyl tetrapeptide-3 into the solution 4, and uniformly stirring to obtain a solution 5;
15 parts of betaine 1, 3-propanediol, 20 parts of GG and 5 parts of 1, 2-pentanediol are added into the solution 5, and after being stirred uniformly, the alopecia preventing composition is obtained.
In a third aspect, the present invention provides the use of an anti-hair loss composition according to the present invention for the preparation of an anti-hair loss product.
The beneficial effects are that: the present invention provides an anti-hair loss composition comprising: matrine salicylic acid, L-carnitine tartaric acid, collagen production promoting polypeptide, keratin production promoting polypeptide, glyceroglycoside, and betaine 1, 3-propylene glycol. The anti-hair loss composition can resist hair loss from multiple dimensions, firstly solves the problem of scalp inflammation caused by excessive secretion of grease of scalp caused by hair follicle blockage by using matrine salicylic acid, achieves the effects of controlling oil, inhibiting bacteria and diminishing inflammation, balances the scalp microorganism environment, combines the moisturizing effect of glucosyl glycerogelatin, and synergistically improves the water-oil balance of scalp; secondly, correcting sub-health states of scalp of the alopecia crowd by utilizing the restoration capability of the glucosyl glyceroglycosides; the polypeptide which promotes collagen generation by combining the L-carnitine tartaric acid is used for improving the activity of hair follicle cells, repairing the hair follicle structure, reinforcing the hair root and avoiding falling off; finally, promoting hair growth by utilizing the polypeptide for promoting keratin generation; the supermolecule permeation promoter can improve the utilization rate of active ingredients and strengthen the efficacy. Betaine 1, 3-propanediol as a supramolecular permeation enhancer not only delivers the composition, but also has a synergistic effect on the active.
Drawings
FIG. 1 is a bar graph of matrine salicylic acid inhibiting IL-1α content.
Fig. 2 is a graph showing the rate of change of oil after use of matrine salicylic acid concentrate.
FIG. 3 is a graph showing the water retention capacity test of glucosyl.
Fig. 4 is a graph of the glucosyl glycoside APQ3 test.
Fig. 5 is another test chart of glucosyl glycoside APQ 3.
FIG. 6 is a graph showing the FLG test of glucosyl glycoside.
FIG. 7 is another test chart of the glyceroglycoside FLG.
FIG. 8 is a graph of a glycerol glucoside cell scratch test.
FIG. 9 is another graph showing the scratch of glucosyl cells.
FIG. 10 is a graph showing cumulative permeation profiles of acetyl tetrapeptide-3.
FIG. 11 is a graph showing the cumulative permeation amount trend of biotin tripeptide-1.
FIG. 12 is a graph showing the results of a keratinocyte cytotoxicity assay.
FIG. 13 is a graph showing the results of human fibroblast-based cytotoxicity assay.
FIG. 14 is a graph showing the results of Wnt pathway-related factor detection.
FIG. 15 is a graph showing the results of VEGF assay.
FIG. 16 is a graph showing the results of IL-6 inhibition assays.
Detailed Description
The invention provides an anti-hair loss composition, a preparation method and application thereof, and aims to make the purposes, technical schemes and effects of the invention clearer and more definite, and the invention is further described in detail below. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the invention.
The embodiment of the invention provides an anti-hair loss composition, which comprises the following components: matrine salicylic acid, L-carnitine tartaric acid, collagen production promoting polypeptide, keratin production promoting polypeptide, glyceroglycoside, and betaine 1, 3-propylene glycol.
In one embodiment, the anti-hair loss composition comprises the following components in parts by weight: 1-10 parts of matrine salicylic acid, 0.5-20 parts of L-carnitine tartaric acid, 0.02-4 parts of polypeptide for promoting collagen production, 0.01-2 parts of polypeptide for promoting keratin production, 5-50 parts of glyceroglycosides and 5-50 parts of betaine 1, 3-propylene glycol.
In one embodiment, the collagen production promoting polypeptide comprises the following components in parts by weight: 0.01-2 parts of biotin tripeptide-1 and 0.01-2 parts of acetyl tetrapeptide-3.
In one embodiment, the polypeptide that promotes keratin production is myristoyl pentapeptide-4.
In one embodiment, the anti-hair loss composition consists of the following components in parts by weight: 1-10 parts of matrine salicylic acid, 0.5-20 parts of L-carnitine tartaric acid, 0.01-2 parts of biotin tripeptide-1, 0.01-2 parts of acetyl tetrapeptide-3, 0.01-2 parts of myristoyl pentapeptide-4, 5-50 parts of glyceroglycosides and 5-50 parts of betaine 1, 3-propylene glycol.
In one embodiment, the anti-hair loss composition consists of the following components in parts by weight: 3 parts of matrine salicylic acid, 0.5 part of L-carnitine tartaric acid, 0.2 part of biotin tripeptide-1, 0.2 part of acetyl tetrapeptide-3, 0.2 part of myristoyl pentapeptide-4, 20 parts of glyceroglycosides and 15 parts of betaine 1, 3-propanediol.
In one embodiment, the anti-hair loss composition further comprises a polyol preservative, preferably 1, 2-pentanediol.
The mechanism of action of the above-mentioned ingredients of the anti-hair loss composition will be described below.
Matrine salicylic acid (belonging to supramolecular ion salts): matrine has antibacterial and antiinflammatory effects, and balanced oil and fat effects, salicylic acid has effects of activating cell activity, shrinking pore, cleaning oil and fat, and antiinflammatory effects, and by supermolecule improvement technique, matrine and salicylic acid are tightly combined by intermolecular force to obtain supermolecule ionic salt, and by test, figure 1, figure 2, and table 5 show that the ionic salt has effect of 1+1> 2. Is used for scalp care, and can control oil, inhibit bacteria, diminish inflammation and balance scalp environment.
Glycerol Glucoside (GG): the compound is a glycoside compound formed by connecting glucosyl and glycerol through glycosidic bonds, is taken as revitalization grass essence, can unlock aquaporin and strengthen cell activity, and is tested to show that GG has moisturizing and repairing capabilities in the figures 3, 4, 5, 6, 7, 8 and 9, so that sub-health states of scalp of alopecia people can be corrected.
Matrine salicylic acid (belonging to supermolecular ion salt) is matched with glyceroglycosides, so that water-oil balance of scalp is further realized, and scalp environmental health is maintained.
L-carnitine tartaric acid (belonging to the supramolecular ionic salts): l-carnitine has the functions of fat oxidative decomposition, fatigue resistance and the like; tartaric acid can relieve skin and regulate sebum excretion. The L-carnitine and the tartaric acid are tightly combined through intermolecular force by a supermolecule improvement technology to prepare supermolecule ion salt, and the effects of the L-carnitine and the tartaric acid are cooperated, so that the accumulation of cutin can be reduced, the sebum excretion can be regulated, the elongation of human hair axes can be promoted, and the activity of hair follicle cells can be effectively improved; on the other hand, the L-carnitine tartaric acid can also be used as a supermolecule permeation promoter to improve the transdermal absorption capacity and the permeability, so that the absorption effect of the composition is enhanced.
Biotin tripeptide-1: the peptide is also called as pilatory peptide, is a tripeptide combining vitamin H and Matrikine series signals GHK, and has the function of tripeptide-1. Can promote synthesis of collagen IV and laminin 5, delay hair follicle aging, promote hair growth, improve hair follicle structure, facilitate fixation of hair in dermis hair follicle, and prevent alopecia.
Acetyl tetrapeptide-3 as bionic peptide can imitate the action of natural peptide of human body, and can accelerate the formation of EMC proteins such as fibronectin, collagen III and VII by fibroblast, thereby increasing the volume of hair follicle, repairing epidermis-dermis connective tissue (DEJ) and promoting hair fixation in hair follicle.
Myristoyl pentapeptide-4: is a cosmetic peptide capable of obviously promoting eyelash growth, and can activate keratin genes to generate more keratin, thereby promoting hair growth, increasing hair growth and thickening, becoming thicker, and having outstanding effects of resisting aging, repairing damaged skin and stimulating collagen synthesis.
Betaine 1, 3-propanediol (as supramolecular permeation enhancer): betaine has effects of strengthening scalp barrier, deeply locking water and keeping moisture, and 1, 3-propylene glycol has osmotic power, and can improve solubility and transdermal absorption of active substances. After the two are formed into a supermolecular solvent, the biotin tripeptide-1, the acetyl tetrapeptide-3 and the myristoyl pentapeptide-4 are wrapped, so that the activity of the three peptides is protected, and the inactivation caused by direct contact with light and heat is avoided; and the transdermal absorption rate and bioavailability of the three peptides are effectively improved due to the amphiphilicity of the supermolecule, the skin permeation and slow release of the three peptides are promoted, the residence time of the three peptides on the skin is prolonged, the absorption and utilization rate is increased, and the transdermal absorption rate and bioavailability of the three peptides are effectively improved.
The embodiment of the invention provides a preparation method of the alopecia preventing composition, which comprises the following steps: matrine salicylic acid, L-carnitine tartaric acid, collagen production promoting polypeptide, keratin production promoting polypeptide, glyceroglycosides and betaine 1, 3-propylene glycol are mixed, and stirred to obtain the alopecia preventing composition.
In one embodiment, the method for preparing the anti-hair loss composition comprises the following steps in parts by weight: 1-10 parts of matrine salicylic acid, 0.5-20 parts of L-carnitine tartaric acid, 0.02-4 parts of polypeptide for promoting collagen production, 0.01-2 parts of polypeptide for promoting keratin production, 5-50 parts of glyceroglycosides and 5-50 parts of betaine 1, 3-propanediol are mixed and stirred to obtain the alopecia preventing composition.
In one embodiment, the preparation method of the alopecia preventing composition specifically comprises the following steps:
s1, placing 3 parts of matrine salicylic acid and deionized water in a beaker, and uniformly stirring to obtain a solution 1;
s2, adding 0.5 part of L-carnitine tartaric acid into the solution 1, and uniformly stirring to obtain a solution 2;
s3, adding 0.2 part of biotin tripeptide-1 into the solution 2, and uniformly stirring to obtain a solution 3;
s4, adding 0.2 part of myristoyl pentapeptide-4 into the solution 3, and uniformly stirring to obtain a solution 4;
s5, adding 0.2 part of acetyl tetrapeptide-3 into the solution 4, and uniformly stirring to obtain a solution 5;
s6, adding 15 parts of betaine 1, 3-propylene glycol, 20 parts of GG and 5 parts of 1, 2-pentanediol into the solution 5, and uniformly stirring to obtain the alopecia preventing composition.
The embodiment of the invention provides an application of the alopecia preventing composition in preparing an alopecia preventing product. The anti-hair loss product can be anti-hair loss shampoo, anti-hair loss conditioner, anti-hair loss essence, anti-hair loss spray and the like, but is not limited to the anti-hair loss shampoo, the anti-hair loss hair conditioner, the anti-hair loss essence, the anti-hair loss spray and the like.
The invention is further illustrated by the following examples.
Example 1
3 parts of matrine salicylic acid and 70.9 parts of deionized water are mixed according to parts by weight, and the mixture is stirred uniformly to obtain a solution 1; adding 0.5 part of L-carnitine tartaric acid into the solution 1, and uniformly stirring to obtain a solution 2; adding 0.2 part of biotin tripeptide-1 into the solution 2, and uniformly stirring to obtain a solution 3; adding 0.2 part of myristoyl pentapeptide-4 into the solution 3, and uniformly stirring to obtain a solution 4; adding 0.2 part of acetyl tetrapeptide-3 into the solution 4, and uniformly stirring to obtain a solution 5; 20 parts of GG and 5 parts of 1, 2-pentanediol were added to the solution 5, and after stirring uniformly, an anti-hair loss composition 1 (designated as sample 1) was obtained.
Example 2
Mixing 3 parts of matrine salicylic acid with 55.9 parts of deionized water, and uniformly stirring to obtain a solution 1; adding 0.5 part of L-carnitine tartaric acid into the solution 1, and uniformly stirring to obtain a solution 2; adding 0.2 part of biotin tripeptide-1 into the solution 2, and uniformly stirring to obtain a solution 3; adding 0.2 part of myristoyl pentapeptide-4 into the solution 3, and uniformly stirring to obtain a solution 4; adding 0.2 part of acetyl tetrapeptide-3 into the solution 4, and uniformly stirring to obtain a solution 5; 15 parts of betaine 1, 3-propanediol, 20 parts of GG, 5 parts of 1, 2-pentanediol were added to the solution 5, and after stirring uniformly, an anti-hair loss composition 2 (designated as sample 2) was obtained.
Example 3
In this example, the alopecia preventing composition 2 is used as a raw material to prepare an alopecia preventing essence, and the formula is as follows:
table 1, anti-hair loss essence recipe
The preparation method of the anti-hair loss essence comprises the following steps:
adding the phase A into a beaker, stirring and heating to about 85 ℃, homogenizing for 4 minutes until no particles exist uniformly, and stirring and cooling after heat preservation for 30 minutes.
Phase B is preheated and dissolved uniformly for standby; phase D is premixed uniformly until the liquid is transparent for standby.
And cooling the phase A to 40 ℃, adding the pre-dissolved phase B, phase C and phase D, and uniformly stirring.
Example 4
In this example, the alopecia preventing composition 2 was used as a raw material to prepare a alopecia preventing spray, which was formulated as follows:
table 2, anti-hair loss spray formulation table
The preparation method of the alopecia preventing spray comprises the following steps:
1. adding the phase A into a beaker, stirring and heating to about 85 ℃, homogenizing for 4 minutes until no particles exist uniformly, and stirring and cooling after heat preservation for 30 minutes.
2. And C phase is premixed uniformly until the liquid is transparent for standby.
3. And cooling the phase A to 40 ℃, adding the phase B and the phase C, and uniformly stirring.
Example 5
In this example, the hair loss preventing composition 2 was used as a raw material to prepare a hair loss preventing shampoo, which had the following formulation:
table 3, shampoo recipe for preventing alopecia
The preparation method of the hair loss preventing shampoo comprises the following steps:
1. adding the phase A into a beaker, stirring uniformly in advance, and heating to about 85 ℃.
2. And B phase: the hydroxypropyl guar hydroxypropyl trimethyl ammonium chloride is pre-dispersed and swelled by deionized water and then treated by citric acid monohydrate to be in a jelly state for standby.
3. And C phase: the polyquaternium-10 is pre-dispersed by deionized water, heated and swelled to be uniform for standby.
4. Adding the pretreated phase B and phase C into the phase A, stirring uniformly, preserving heat for 20 minutes, and starting stirring and cooling.
5. E phase: pre-mixing uniformly until the liquid is transparent for standby.
6. And (4) after the temperature is reduced to 40 ℃, adding the phase D, the phase E and the phase F, and stirring uniformly.
Test example 1
Anti-inflammatory, oil control and bacteriostasis tests are carried out on matrine salicylic acid.
1. IL-1. Alpha. Inflammatory factor inhibition test:
the results of the detection using IL-1α ELISA kit (Abcam) are shown in FIG. 1, and it can be seen from FIG. 1 that:
compared with a blank control group (BC), the IL-1 alpha content of the negative control group (NC) is obviously increased, which indicates that the experiment is effective;
compared with a negative control group (NC), the IL-1 alpha content of the positive control group (PC) is obviously reduced, which indicates that the experiment is effective;
compared with the negative control group (NC), the content of the matrine salicylic acid group IL-1 alpha is obviously reduced, which proves that the matrine salicylic acid greatly inhibits the secretion of the IL-1 alpha, thereby inhibiting inflammatory cascade reaction caused by the IL-1 alpha.
2. And (3) oil control test:
matrine salicylic acid is prepared into essence, and the formula components are as follows:
table 4, matrine salicylic acid essence formulation table
Randomly selecting half faces of the subjects as blank control areas, and the other half faces as tested areas. The skin data before the face of the subject is used for the product is collected by using a skin measuring instrument, and the return visit test is carried out after one week, two weeks, three weeks and four weeks after the product is used, and the data before the use, the test results of 7D, 14D, 21D and 28D are collected together, and the results are shown in figure 2. As can be seen from fig. 2, volunteers using matrine salicylic acid essence all showed a continuous decrease in oil rate after 7 days, indicating an oil control effect after 7 days of application of matrine salicylic acid.
3. Bacteriostasis test:
adding 2mL of matrine salicylic acid solution with different dilutions into a glass test tube containing 2mL of double nutrient broth culture medium, and collecting bacteria with a bacterial content of about 1×10 4 cfu/mL~5×10 6 Inoculating cfu/mL bacterial liquid into test tubes containing different dilutions and culture mediums, and inoculating the bacterial liquid into test tubes of the culture mediums without the sample liquid in the same way to serve as positive control; in the same manner, the test tube without inoculating the bacterial liquid was placed in an incubator at 37℃for culturing (fungus in an incubator at 28℃for 48 hours) for observation for 18-24 hours.
The results are shown in Table 5:
TABLE 5 inhibition of strains by matrine salicylic acid solution
Malassezia is a fungus that uses sebum as a "food," which is essentially a lambkin that colonizes the skin with oil and is common to us. Once the sebaceous gland is secreted vigorously, the malassezia can excessively reproduce, and the metabolite lipolytic enzyme of the malassezia can change triacylglycerol in hair follicles into free fatty acid, stimulate the hair follicle to produce multiple desquamation, so that the hair follicle duct is blocked and ruptured, and inflammatory reaction is caused. Inhibition of malassezia reduces irritation of multiple hair follicles.
As can be seen from table 5:
matrine salicylic acid has inhibiting effect on Staphylococcus aureus, escherichia coli, candida albicans, propionibacterium acnes, and Malassezia furfur.
In conclusion, the matrine salicylic acid has the effects of controlling oil, diminishing inflammation and inhibiting bacteria.
Test example 2
And carrying out moisturizing and repairing tests on the glyceroglycosides liquid.
Water retention capability test:
the water loss rate can be measured by a weighing method to represent the water retention capacity of the raw material. 2% GG (2% of glyceroglycosides and 98% of deionized water), 2% of glycerol (2% of glycerol and 98% of deionized water), 0.1% of HA (0.1% of HA and 99.9% of deionized water) and ultrapure water (negative) are selected for weight loss test, wherein the weight percentage is expressed as percentage by mass; the percentage (weight loss of water-weight loss of feedstock) is shown in fig. 3.
Conclusion of experiment:
the water retention capacity of 2% GG is better than that of 2% glycerol, and the water retention capacity of 2% GG in 9 h is equivalent to that of 0.1% HA, which shows that GG has certain moisture retention capacity.
Aquaporin 3 test:
aquaporin 3 (APQ 3) test was performed based on keratinocyte against GG, and the results are shown in fig. 4 and 5:
as can be seen from fig. 4:
based on keratinocytes, the positive control group (PC) AQP3 protein is obviously increased compared with the blank control group (BC), which indicates that the positive control detection is effective; the AQP3 protein was significantly elevated in the GG group compared to the control group (BC). The GG group can obviously improve the expression quantity of AQP3 and has a certain moisturizing effect.
3. Barrier repair related protein gene testing:
FLG is the main component of the epidermal granule cell keratin granule, and besides the structural composition of skin barrier, FLG can be hydrolyzed into natural moisturizing factors in Caspase-14, so that the moisturizing effect is also achieved.
FLG tests were performed for GG based on 3D epidermis model, the results are shown in fig. 6 and 7:
as can be seen from fig. 6:
compared with a blank control group (BC), the positive control group (PC) FLG protein is obviously increased based on the 3D epidermis model, which indicates that the positive control detection is effective; the FLG protein was significantly elevated in the GG group compared to the Blank (BC). The GG group can obviously improve the expression quantity of FLG, and has a certain moisturizing effect.
Scratch test:
the scratch test was performed on the basis of human keratinocytes against GG, and the results are shown in fig. 8 and 9, as can be seen from fig. 8 to 9:
at 24h, compared with the negative control group (NC), the scratch relative area of the positive control group (PC) is obviously reduced, and the scratch relative area of the sample GG is obviously reduced at the concentration of 10 mg/mL; at 48h, compared with the negative control group (NC), the scratch relative area of the positive control group (PC) is obviously reduced, and the scratch relative area of the sample GG is obviously reduced at the concentration of 5mg/mL, 10 mg/mL and 30 mg/mL; it is shown that GG has repair function.
Taken together, it is shown that the glucosyl glycoside has the effects of moisturizing and repairing.
Test example 3
Percutaneous absorption tests were performed for example 1 and example 2:
the skin penetration performance of the anti-hair loss composition was evaluated by measuring the cumulative transdermal amount of the polypeptide at each time point by performing an in vitro skin penetration test using pig skin as a model through a Franz diffusion cell.
As can be seen from fig. 10 and 11, 24h polypeptide accumulated permeabilities:
in combination with the cumulative permeation trend graph, the release time of the acetyl tetrapeptide-3 and the biotin tripeptide-1 of the sample 2 is earlier than that of the sample 1, and the overall release trend is stable and continuous, so that the transdermal absorption of the polypeptide can be increased and the effect of promoting the hair growth in the skin can be more effectively exerted after the supermolecule permeation enhancer (namely betaine 1, 3-propanediol) is contained in the sample 2.
Test example 4
Safety test:
the effect of sample 2 on the viability of keratinocytes and human fibroblasts was investigated by the following method:
1. based on the keratinocyte cytotoxicity test, the results are shown in fig. 12. As can be seen from fig. 12, sample 2 obtained in example 2 has a relative survival rate of 90 or more for keratinocytes based on keratinocytes in the range of 0.625%, and IC 50= 1.4578% (95% ci:1.3574% -1.5582%) in the safe concentration range of 0.625%.
2. The results are shown in FIG. 13 based on human fibroblast toxicity assay. As can be seen from fig. 13, sample 2 obtained in example 2 was based on human fibroblasts, and the anti-hair loss composition had ic50= 1.4124% (95% ci:1.2104% -1.6144%).
3. The chick embryo chorioallantoic membrane vessel test gave the following results in Table 6.
Table 6, results of experiments on toxicity effect of sample 2 on chick embryo chorioallantoic membrane
As can be seen from Table 6 above, the anti-hair loss composition was non-irritating to the chicken embryo chorioallantoic membrane with RC50:17.16% (95% CI: 17.16%).
Test example 5
Efficacy testing was performed on sample 2:
1. wnt pathway correlation factor test results are shown in figure 14.
Compared with a blank control group (BC), the beta-catenin gene amplification multiple of the negative control group (NC) is obviously reduced, which proves that the test stimulation condition is effective;
compared with a negative control group (NC), the beta-catenin gene amplification multiple of the positive control group (PC) is obviously improved, which proves that the positive condition of the test is effective;
compared with a negative control group (NC), the anti-hair loss composition 2 shows a remarkable lifting effect on the beta-catenin gene, which indicates that the anti-hair loss composition 2 can promote proliferation of hair papilla cells and promote hair regeneration.
2. VEGF testing results are shown in FIG. 15.
VEGF is a known important vascular endothelial growth factor, is a highly specific pro-vascular endothelial growth factor, and has the effects of promoting vascular permeability increase, extracellular matrix degeneration, vascular endothelial cell migration, proliferation, angiogenesis and the like. Thus, the decrease in VEGF directly leads to insufficient vascularization, an important factor in hair follicle atrophy.
Compared with a blank control group (BC), the VEGF secretion level of the negative control group (NC) is extremely obviously reduced, which proves that the test stimulation condition is effective;
compared with a negative control group (NC), the VEGF secretion level of the positive control group (PC) is extremely obviously increased, which proves that the positive condition of the test is effective;
compared with a negative control group (NC), the anti-hair loss composition 2 can obviously increase the VEGF content, which shows that the anti-hair loss composition 2 can increase the blood vessel density and the blood vessel permeability around hair follicles, nourish the hair follicles, promote the supply of oxygen and nutrients required by hair growth, and further achieve the effect of fixing hair.
3. IL-6 inflammatory factor inhibition test, the results are shown in FIG. 16.
Compared with a blank control group (BC), the IL-6 secretion level of the negative control group (NC) is obviously increased, which proves that the test stimulation condition is effective;
compared with a negative control group (NC), the IL-6 secretion level of the positive control group (PC) is extremely obviously reduced, which proves that the positive condition of the test is effective;
compared with a negative control group (NC), the anti-alopecia composition 2 can obviously reduce the content of IL-6, which proves that the anti-alopecia composition 2 has a certain effect on correcting abnormal expression of signal molecules causing androgenetic alopecia, thereby achieving a certain degree of anti-inflammatory, hair-strengthening and hair-growing effects.
In summary, the present invention provides an anti-hair loss composition, and a preparation method and application thereof, wherein the anti-hair loss composition comprises: matrine salicylic acid, L-carnitine tartaric acid, polypeptide for promoting collagen production, polypeptide for promoting keratin production, and betaine 1, 3-propylene glycol. The anti-hair loss composition can be used for resisting hair loss from multiple dimensions, firstly, the problem of scalp inflammation caused by excessive secretion of grease from scalp caused by hair follicle blockage is solved by using matrine salicylic acid, the effects of controlling oil, inhibiting bacteria and diminishing inflammation are achieved, the scalp microbial environment is balanced, and the moisturizing effect of the glucosinolates is combined to synergistically improve the water-oil balance of the scalp; secondly, correcting sub-health states of scalp of the alopecia crowd by utilizing the restoration capability of the glucosyl glyceroglycosides; the polypeptide which promotes collagen generation by combining the L-carnitine tartaric acid is used for improving the activity of hair follicle cells, repairing the hair follicle structure, reinforcing the hair root and avoiding falling off; finally, promoting hair growth by utilizing the polypeptide for promoting keratin generation; the supermolecule permeation promoter can improve the utilization rate of active ingredients and strengthen the efficacy. The supermolecule penetration enhancer not only can deliver the composition, but also is a common component in cosmetics, and can play a role in synergy on the active substances.
It is to be understood that the invention is not limited in its application to the examples described above, but is capable of modification and variation in light of the above teachings by those skilled in the art, and that all such modifications and variations are intended to be included within the scope of the appended claims.
Claims (3)
1. The anti-hair loss composition is characterized by being prepared from the following preparation methods in parts by weight:
mixing 3 parts of matrine salicylic acid with 55.9 parts of deionized water, and uniformly stirring to obtain a solution 1;
adding 0.5 part of L-carnitine tartaric acid into the solution 1, and uniformly stirring to obtain a solution 2;
adding 0.2 part of biotin tripeptide-1 into the solution 2, and uniformly stirring to obtain a solution 3;
adding 0.2 part of myristoyl pentapeptide-4 into the solution 3, and uniformly stirring to obtain a solution 4;
adding 0.2 part of acetyl tetrapeptide-3 into the solution 4, and uniformly stirring to obtain a solution 5;
15 parts of betaine 1, 3-propanediol, 20 parts of glyceroglycosides and 5 parts of 1, 2-pentanediol are added into the solution 5, and after being stirred uniformly, the alopecia preventing composition is obtained.
2. A method for preparing the alopecia preventing composition according to claim 1, wherein the preparation method comprises the following steps in parts by weight:
mixing 3 parts of matrine salicylic acid with 55.9 parts of deionized water, and uniformly stirring to obtain a solution 1;
adding 0.5 part of L-carnitine tartaric acid into the solution 1, and uniformly stirring to obtain a solution 2;
adding 0.2 part of biotin tripeptide-1 into the solution 2, and uniformly stirring to obtain a solution 3;
adding 0.2 part of myristoyl pentapeptide-4 into the solution 3, and uniformly stirring to obtain a solution 4;
adding 0.2 part of acetyl tetrapeptide-3 into the solution 4, and uniformly stirring to obtain a solution 5;
15 parts of betaine 1, 3-propanediol, 20 parts of glyceroglycosides and 5 parts of 1, 2-pentanediol are added into the solution 5, and after being stirred uniformly, the alopecia preventing composition is obtained.
3. Use of the anti-hair loss composition of claim 1 in the preparation of an anti-hair loss product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310886126.2A CN116617356B (en) | 2023-07-19 | 2023-07-19 | Alopecia preventing composition, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310886126.2A CN116617356B (en) | 2023-07-19 | 2023-07-19 | Alopecia preventing composition, and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116617356A CN116617356A (en) | 2023-08-22 |
| CN116617356B true CN116617356B (en) | 2023-11-21 |
Family
ID=87638532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310886126.2A Active CN116617356B (en) | 2023-07-19 | 2023-07-19 | Alopecia preventing composition, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116617356B (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101890080A (en) * | 2010-08-02 | 2010-11-24 | 西北大学 | Hair-loss preventing and hair-restoring medicinal composition and preparation method thereof, shampoo containing medicinal composition and preparation method thereof |
| CN105106028A (en) * | 2015-08-28 | 2015-12-02 | 深圳市维琪医药研发有限公司 | Polypeptide composition for hair growth |
| CN109575024A (en) * | 2018-12-21 | 2019-04-05 | 深圳市萱嘉生物科技有限公司 | A kind of matrine phenolate and the preparation method and application thereof |
| CN113332201A (en) * | 2021-06-08 | 2021-09-03 | 钟娟 | Anti-hair loss shampoo and preparation method thereof |
| CN113980086A (en) * | 2021-11-02 | 2022-01-28 | 深圳市萱嘉生物科技有限公司 | Glycyrrhizic acid matrine amino acid ion salt, preparation method and application thereof |
| CN114306173A (en) * | 2022-02-11 | 2022-04-12 | 广州华厦生物制药有限公司 | Hair loss preventing essence and preparation method thereof |
| CN115252649A (en) * | 2022-09-28 | 2022-11-01 | 广州集妍化妆品科技有限公司 | Application of thermophilic bacteria fermentation product in preventing alopecia and/or growing hair, composition and preparation thereof |
| CN115969737A (en) * | 2022-12-08 | 2023-04-18 | 深圳市萱嘉生物科技有限公司 | Supermolecular liposome freeze-dried mask and preparation method and application thereof |
| CN116370589A (en) * | 2023-02-22 | 2023-07-04 | 深圳津梁生活科技有限公司 | Preparation method and application of hair-loss prevention hair-growing composition |
-
2023
- 2023-07-19 CN CN202310886126.2A patent/CN116617356B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101890080A (en) * | 2010-08-02 | 2010-11-24 | 西北大学 | Hair-loss preventing and hair-restoring medicinal composition and preparation method thereof, shampoo containing medicinal composition and preparation method thereof |
| CN105106028A (en) * | 2015-08-28 | 2015-12-02 | 深圳市维琪医药研发有限公司 | Polypeptide composition for hair growth |
| CN109575024A (en) * | 2018-12-21 | 2019-04-05 | 深圳市萱嘉生物科技有限公司 | A kind of matrine phenolate and the preparation method and application thereof |
| CN113332201A (en) * | 2021-06-08 | 2021-09-03 | 钟娟 | Anti-hair loss shampoo and preparation method thereof |
| CN113980086A (en) * | 2021-11-02 | 2022-01-28 | 深圳市萱嘉生物科技有限公司 | Glycyrrhizic acid matrine amino acid ion salt, preparation method and application thereof |
| CN114306173A (en) * | 2022-02-11 | 2022-04-12 | 广州华厦生物制药有限公司 | Hair loss preventing essence and preparation method thereof |
| CN115252649A (en) * | 2022-09-28 | 2022-11-01 | 广州集妍化妆品科技有限公司 | Application of thermophilic bacteria fermentation product in preventing alopecia and/or growing hair, composition and preparation thereof |
| CN115969737A (en) * | 2022-12-08 | 2023-04-18 | 深圳市萱嘉生物科技有限公司 | Supermolecular liposome freeze-dried mask and preparation method and application thereof |
| CN116370589A (en) * | 2023-02-22 | 2023-07-04 | 深圳津梁生活科技有限公司 | Preparation method and application of hair-loss prevention hair-growing composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116617356A (en) | 2023-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109731001B (en) | New application of new agaro-oligosaccharide and composition containing new agaro-oligosaccharide | |
| US20230106788A1 (en) | Cosmetic composition comprising dead lactic acid bacteria lactobacillus plantarum mass or culture of lactic acid bacteria for preventing or alleviating skin aging | |
| CN105902461A (en) | Essence containing snail mucus extracts and preparation method thereof | |
| CN110302086A (en) | A kind of multiple-effect maintenance essence and its preparation process | |
| CN110123695B (en) | Cell energy restoration composition | |
| US10786443B2 (en) | Method for protecting skin by using orchid callus extract | |
| CN110200837B (en) | Hair growth composition | |
| CN113332162B (en) | protamine-PDRN compound, composition and application in preparation of skin care product | |
| JP2018538256A (en) | PALMARIA Synergistic extract of PALMATA and jasmine, compositions containing it and their use | |
| KR20150120426A (en) | Cosmetic composition containing a brown alga extract, a yeast extract and ascorbic acid | |
| CN115554187B (en) | Mussel mucoprotein skin repairing emulsion capable of achieving wet and heat sterilization and preparation method thereof | |
| CN114712275A (en) | Anti-wrinkle repair composition and preparation method thereof, and cosmetic and preparation method thereof | |
| US10973755B2 (en) | Method for treating skin aging and photodamage by using Camellia sinensis callus extract | |
| CN116509774B (en) | Anti-dandruff shampoo preparation containing sweet wormwood herb extract and preparation method thereof | |
| CN116850114B (en) | Composition for relieving and repairing and cream for relieving and repairing | |
| CN116617356B (en) | Alopecia preventing composition, and preparation method and application thereof | |
| CN112656731A (en) | Composition with red-repairing effect and preparation method and application thereof | |
| JP2021531244A (en) | A pharmaceutical composition for wound healing or skin activation containing beta-glucan, glycitin and 4', 6,7-trimethoxyisoflavone. | |
| CN111743826A (en) | Freckle-removing, wrinkle-resisting and moisturizing emulsion | |
| CN115813774A (en) | Water-oil double-layer refined composition with whitening effect and preparation method and application thereof | |
| KR102076178B1 (en) | Cosmetic composition for improving skin wrinkle containing colostrum and ornithine | |
| KR20180124438A (en) | Cosmetic composition comprising oligo-hyaluronic acid exhibiting up-regulation of aquaporin-3 and anti-inflammatory effect | |
| KR20090003828A (en) | Hair tonic containing composite for growig hair and preventing fall-out of hair | |
| CN113456547B (en) | Skin care composition with allergy-relieving and anti-inflammatory effects and application thereof | |
| CN114886794B (en) | Composition with anti-inflammatory and antioxidant effects and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |